A proposed SPC manufacturing waiver – which would allow generic and biosimilar manufacturing within Europe during the SPC period – has taken a step closer to being realized after the European Council approved a mandate for negotiations with the European Parliament. However, it remains uncertain whether key elements desired by the off-patent industry will fall into place.
A mandate for negotiations with the European Parliament on a draft Regulation outlining a waiver to allow manufacturing during the term of supplementary protection certificates (SPCs) has been approved by the European Council.
The move brings the long-awaited SPC manufacturing waiver a step closer to fruition, although it remains uncertain whether key elements...